Quantcast

Latest Eisai Inc. Stories

2014-04-25 08:27:40

WOODCLIFF LAKE, N.J., April 25, 2014 /PRNewswire/ -- Eisai Inc. announced today that six abstracts highlighting data analyses for FYCOMPA(TM) (perampanel) will be presented at the 66(th) annual American Academy of Neurology (AAN) meeting, taking place in Philadelphia, PA from April 26( )- May 3. http://photos.prnewswire.com/prnvar/20120413/MM87168LOGO "Eisai and its epilepsy franchise are committed to expanding its knowledge of current products and developing new medications for the...

2014-04-14 12:34:04

SAN DIEGO, April 14, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. The initial advertisement, which illustrates the struggles that many people face with hunger and body weight, will air on Lifetime, Oxygen, AMC and numerous other networks. BELVIQ is presented as a targeted approach to...

2014-04-14 12:27:47

Campaign Creates Awareness of Prescription Drug Option for Chronic Weight Management WOODCLIFF LAKE, N.J., April 14, 2014 /PRNewswire/ -- Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ(®) (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC. To view the multimedia assets associated with this release, please click:...

2014-03-31 04:20:57

WOODCLIFF LAKE, N.J., March 31, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN(®) (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan. Eisai will retain its rights for DACOGEN(®) in Mexico. In...

2014-03-13 08:29:07

Sisters Network® Inc. launches innovative pilot program designed to help address breast cancer disparities affecting the African American community HOUSTON and WOODCLIFF LAKE, N.J., March 13, 2014 /PRNewswire/ -- Sisters Network, the only national African American breast cancer survivorship organization, announced today the launch of Teens 4 Pink, a new program that aims to educate and empower African American teens to change the way their family members think and act about breast...

2014-03-10 08:30:23

Company Appoints New Executive Leaders WOODCLIFF LAKE, N.J., March 10, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the appointments of Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, effective April 1, 2014. Mr. Matsue and Ms. Procida succeed current President and CEO Lonnel Coats, who will be retiring from Eisai in June 2014 after 18 years. Over the next few months,...

2014-02-27 08:30:00

Patient Recruitment Now Underway at Treatment Centers Across the United States WOODCLIFF LAKE, N.J., Feb. 27, 2014 /PRNewswire/ -- Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second- line treatment for HER2-negative locally recurrent or metastatic breast cancer (MBC). Recruitment is currently active for this multicenter study, conducted in...

2014-02-24 08:28:05

Patient Recruitment and Enrollment Now Underway WOODCLIFF LAKE, N.J., Feb. 24, 2014 /PRNewswire/ -- Eisai Inc. today announced that patient recruitment and enrollment are currently underway for CAMELLIA-TIMI 61, a randomized double-blind, placebo-controlled outcomes trial to evaluate the effect of long-term treatment with lorcaserin HCl on the incidence of major adverse cardiovascular events and new onset type 2 diabetes mellitus in obese (BMI > 30 kg/m(2)) and overweight (BMI > 27...

2014-02-10 08:26:31

-- BELVIQ Now Covered by CVS Caremark -- SAN DIEGO, Calif., Feb. 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai has secured improved patient access of BELVIQ(®) (lorcaserin HCl) with two leading healthcare benefit companies, and that the estimated number of insured commercial lives in the United States that have coverage for BELVIQ now exceeds 50 percent. CVS Caremark customers (employers and health plans) have broadened the coverage of...

2014-02-10 08:26:18

Number of Insured Commercial Lives in the U.S. with Coverage for BELVIQ® Now Exceeds 50 Percent WOODCLIFF LAKE, N.J., Feb. 10, 2014 /PRNewswire/ -- Eisai Inc. reported today that it has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit companies: CVS Caremark and Aetna. CVS Caremark customers (employers and health plans) have broadened the coverage of Eisai's BELVIQ, according to Fingertip Formulary, an integrated database of formulary...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related